{"database": "openregs", "table": "federal_register", "rows": [["2012-3234", "Draft Guidance for Industry on Bioequivalence Recommendations for Rifaximin Tablets; Availability", "Notice", "The Food and Drug Administration (FDA) is announcing the availability of two draft guidances for industry entitled ``Bioequivalence Recommendations for Rifaximin,'' one for the 200- milligram (mg) strength (rifaximin-200) and one for the 550-mg strength (rifaximin-550). The recommendations provide specific guidance on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for rifaximin tablets.", "2012-02-13", 2012, 2, "https://www.federalregister.gov/documents/2012/02/13/2012-3234/draft-guidance-for-industry-on-bioequivalence-recommendations-for-rifaximin-tablets-availability", "https://www.govinfo.gov/content/pkg/FR-2012-02-13/pdf/2012-3234.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA) is announcing the availability of two draft guidances for industry entitled ``Bioequivalence Recommendations for Rifaximin,'' one for the 200- milligram (mg) strength (rifaximin-200) and one for the 550-mg...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2012-3234"], "units": {}, "query_ms": 0.49821101129055023, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}